Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Swing trading is used by professionals in currency trading, forex trading and stock trading with amazing results. Learning how to swing trade and using it as your trading style or strategy will give you the much needed edge over the market and help you become a profitable and professional trader online or offline. On this website, you’ll find only the best and most powerful trading tips, tools and secrets to put you on the path to trading successfully.
Or follow us on Twitter.
Independent investor with extensive financial experience. Numerous years of trading securities, personal portfolio manager. Main interests are in tech and banking. Personal focus is on tech growth opportunities and deep value plays in the banking sector. Happy to respond to article comments, but often unable to do so because of hectic work schedule.
Biomed Group is an independent research group, with a goal of providing investors with real-time information and exclusive specialised research on biotechnology stocks, so that they can make informed investment decisions.
I spent 15+ years in accounting and finance, mainly in financial analysis, reporting, auditing, and some tax preparation. I have a degree in finance and a CPA certificate, but no, I am not licensed to practice anymore. It was a personal choice. I was never thrilled with bean-counting, and my real interest was in meteorology. Plus, the commitment to keeping up my license and dealing with the ridiculous changes in the tax code, financial reporting, and other aspects has me keeping my distance. Case in point, SOX, did wonders to stop our banking execs from defrauding and crashing our financial system. Yeah, right. How much did the legislation and enforcement cost the taxpayer vs. what the taxpayer received in return? Besides, I found out I am a better trader. Not quite meteorology, but on the west coast, I am done by 1pm, which leaves plenty of time for hiking and other outdoor activities. If you can appreciate nature, you will get more out life, and appreciate the things that matter to you the most. This is a perfect compliment to the rat-race and greed that envelope our markets on a daily basis.
Market Trend Signal™ is the leader in Trend Following, Market Timing and Stock Ratings.
Market Trend Signal clients receive access to stock ratings on over 15000 stocks as well as market timing trend following signals on all major markets and sectors.
Market Trend Signal™ provides users with an easy to use market timing system to determine whether the stock market is providing favorable or unfavorable trading conditions.
Our investment analysis and stock ratings are based solely on price. This method is a trend following method. Our proprietary market timing signals and stock ratings find strong stocks in rising industries again and again, and will ALWAYS identify best of breed stocks using our StrengthRank setting. We place a very simple BUY, SELL or HOLD stock rating with a short term trend following signal for early indication of a shifting entry or exit signal.
It is our objective to provide every individual with a Market Timing System and trend following system, to allow success in investing and trading.
In an ever changing economic environment investors need a serious, disciplined approach to trading, trend following, market timing
I'm an independent equity researcher, writer and investor based in Amsterdam. My primary focus is on the micro-cap segment of the market. I also work for pension funds as a member of the Board and Investment Committee. Lastly, I enjoy soccer, sports in general and brewing the best coffee one can make at home.
Post-graduate student in chemical + bioengineering, get my kicks by learning about things that interest me! Looking to use my expertise and knowledge to better communicate biotech trade ideas to the average investor.
Shane Skinner has invested in biotech companies for almost 20 years and placed over $2.6 million in biotech stock trades in 2013. He has held various financial leadership positions over the past 17 years throughout the United States and Europe including Chief Financial Officer. Shane graduated from Pepperdine University with an MBA, York College with a bachelor's degree in accounting, and is a licensed CPA. He was a collegiate soccer and rugby player and still plays in recreational leagues in Seattle. He has a wife, son, and one on the way!
Jonathan Moreland is the founder and Director of Research at InsiderInsights.com, which produces the weekly InsiderInsights Newsletter, and offers institutional strength, real-time insider data and analytics via a subscription Data Module and APIs. He is also principal of Insider Asset Management llc, a registered investment advisor in New York State, and a past contributor to TheStreet.com, Minyanville, and other financial outlets.
A fundamental analyst with an MBA in finance, Mr. Moreland identified insider data over 25 years ago as an excellent first screen to determine where to focus his research efforts. He is quoted frequently in the media for his insider analysis, and stock recommendations stemming from it. He is also author of Profit From Legal Insider Trading (Dearborn 2001), and has a new book due out with Wiley.
Mr. Moreland is currently on a mission to get investors to expect more from insider data than the commodity feeds they rely on from their Bloomberg terminals, Yahoo!Finance, and other financial websites.
I've made the decision to no longer contribute content on this platform. I've done so due to irreconcilable differences of opinion with the editors of Seeking Alpha regarding what I believe to be inconsistent, absent and deeply biased editorial oversight. Favoritism is the motive that moves these decisions and is granted not on the basis of merit, but on thematic considerations (short-position articles are given massive leeway) and on pragmatic considerations (who can make Seeking Alpha the most money). For readers, this creates a problematic environment where a marketplace of competing ideas is crushed in favor of compliance to preconceived and sterile thinking. Participation in "The Marketplace" is coerced in order for one's contributions to be labelled "premium" even if that content is far from the meaning that the word "premium" implies. Additionally, certain contributors are allowed to play by their own rules and in so doing the well being of all investors is compromised. While I applaud the idea of moving the markets through well researched and articulated ideation, I deplore manipulation of the market through false pretense and deliberate, unethical and morally repugnant activities. When I have brought my concerns to the editors, I've been told unequivocally that these matters don't concern them or, alternatively, that they do not wish to play the role of regulators. In both instances, I find these responses unacceptable if only because the core idea of Seeking Alpha as the democratization of the stock market through the publication of buy-side analysis is so worth protecting. I leave you, my readers, with a deep sense of gratitude for all the encouragement you've given me. In my absence, I ask only that you do your own due diligence and recognize that the opinions of bloggers, such as myself, are not to be acted upon. No opinion expressed by any contributor, most especially myself, constitutes an offer or suggestion to buy, sell, or hold any security. Always consult an investment professional before making any investment decision. In the absence of professional guidance, learn all that you can about one particular sector of investment. Follow the development of not only the companies involved, but the science, technology and persons associated with the business sector you've chosen. Remember your successes and learn from your mistakes.
Always be well...
P.S. Scrying Biotech is not, and has never been a pseudonym. It's just the coolest logo in biotech blogging. My name is, Michael Webb. And I live in the greatest city on earth - Seattle, Washington.
Cited by Barron's as one of the top financial websites to visit on the weekend, Financial Sense (www.financialsense.com) provides educational resources to the broad public audience through a daily podcast, editorials, current news and resource links on salient financial market issues. Begun in 1985 as a local talk radio program, Financial Sense Newshour (www.financialsense.com/financial-sense-newshour) is a weekly webcast with host Jim Puplava and top financial thinkers. Writing staff of Financial Sense includes: Jim Puplava, Chris Puplava, Ryan Puplava, and Cris Sheridan.
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future.
QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
I am a psychologist at the University of Massachusetts/Amherst. I am on our campus’s Institutional Review Board, which must conclude that proposed studies involving human subjects are conducted ethically and are designed well enough so that any risks involved are justified by the likely benefits obtained.
I teach about analytical reasoning, leadership skills, reconciling apparently incompatible positions, designing, implementing, and evaluating policies, and how to critically evaluate competing health claims based on the samples studied and methods of data collection and analysis used.
Most of my investments involve owning medical industry stocks.
I like exposing Penny Stock Pump and Dumps. Most of my research is done to help good hard working people avoid being scammed into investing in a pump and dump. Share the reports to show Seeking Alpha they are worth publishing this kind of information to help people avoid losing money in pump and dumps.
Disclaimer and disclosure: It is probable that the author and his associates have a position in the subject securities consistent with the opinion expressed in this article and they reserve the right to buy and/or sell the securities mentioned in this article, at any time without further notice.
Zorro Trades attempts to utilize fundamental analysis to identify securities and then gain an idea of when to enter said security via technical analysis.
A biopharma portfolio manager as well as a sell-side biotechnology analyst for the past 20 years. In 2005, formed the Lyons Share Group, providing independent biopharma research and consulting services to institutional portfolio managers with regard to investments in the sector that fit the market capitalzation and investment styles. MBA from the Fuqua School of Business, Duke University and a Chartered Financial Analyst.
I am the President of TFST Publishing which is a Stock Advisory Service . We publish The Focused Stock Trader an online newsletter www.thefocusedstocktradercom
I have been a stock broker, investment banker, and CEO of 2 micro-cap companies ( see LinkedIn). At the present time I am focused on my newsletter which ended 2013 with 85 profitable trades out of 95 recommendations, for an annualized return of 265%. The Focused Stock Trader recommended the purchase of 49 stocks in 2013. The 49 stocks that were recommended had an average high 64% above The Focused Stock Trader’s recommendation price. The top ten trades all had a high at least 90% above The Focused Stock Trader’s recommendation price. OVERALL THE TOP TEN RECOMMENDATIONS HIGH PRICE HAD AN AVERAGE RETURN OF 170% ABOVE THE FOCUSED STOCK TRADER’S INITIAL RECOMMENDATION PRICE.
You can also follow us on Facebook @ Facebook.com/TheFocusedStockTrader Twiter and LinkedIn
I hold multiple undergraduate degrees with concentrated focus in the fields of Psychology, Sociology, History, and Economics. Prior to working as an independent strategist for a handful of clients, I was employed as a behavioral economist for a private London based group. Before that, I worked for domestic entities such as FBR and ACC Capital.
In terms of equities analysis, my focus is strictly on long term investments, emerging biotechnology entities, distressed or undervalued companies, and maritime commerce. In terms of market analysis, my focus is on the market implications of social and non-traditional factors. I do not discredit more traditional technical and fundamental analysis, but I value greatly the largely underrated, and often forgotten, historical evolution of capitalism and capital market psychology. Thus, some articles I write will be highly speculative and unorthodox, and will likely represent a minority opinion. Others, when undervaluation is a motivating factor for the article having been written, will be highly technical and metric based.
Also, I urge readers to consider the premise of investment horizon, and authorship intention, when reading my contributions. Many of the articles for companies which I endorse will be deemed "long term", which I generally consider to be no less than 2-3 years unless otherwise noted. Moreover, some articles are written simply to test a potential investment thesis in an effort to garner feedback about prospective positions. In the latter, the "Risk" segment of articles will be thoroughly detailed and should be heavily weighed. Many such pieces will be long "ideas", not necessarily long "recommendations" or "endorsements", and it is imperative that readers understand that prior to any assumptions being made or conclusions being drawn. Thus, I would implore readers to consider my articles carefully and thoroughly, and to ask any questions they may have pertaining to publication purpose if not otherwise clearly defined. I will always do my best to respond in a timely fashion.
Lastly, I am a fervent proponent of the value brought to investments by behavioral finance theory, and I utilize this premise in all equities analysis.
Anonymity Disclosure: I am fully cognizant of the fact that some readers question the integrity and/or accountability of anonymous contributors. Please know that my preference for privacy is a two fold consideration; (1) I remain under a revolving open contract to consult for an entity where I signed a lifetime NCND agreement. In order not to risk violating any potential terms of that agreement, now or in the future, I maintain a very low web based profile. (2) I am a proponent of unbiased analysis being openly shared among prospective investors. However, in order to ensure no collisions occur between professional patronage and personal privacy, I have elected to utilize anonymity as the barrier between the two.
Zacks.com brings the decades of study and stock picking expertise of Zacks Investment Research to individual investors. Now, you don't to be an investment bank or brokerage firm to get the professional power of Zacks' research. It's all available on Zacks.com. Learn more about Zacks' history and company below.
StockMatusow.com Writers are:
Scott Matusow; Team Leader, owner and founder of StockMatusow.com.
Scott is an independent investor/writer/trader and team leader of StockMatusow.com.
He has have about fifteen years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.
Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things 'outside the box.' Scott uses his ability to read situations and emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements. Using these allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis.
Scott has his own online talk show which can be heard at www.scottmatusow.com/radio .
During market hours, we engage in talk about Stocks and Politics. After hours, Scott engages in a variety of talk issues from Poker, Sports, Politics, Current Events and whatever the chat room people wish to talk about.
Other places you can follow Scott are:
Kyle Dennis; writer, analyst, trader, website design, and team member of Stockmatusow.com.
Kyle has a Biology degree from the University of California Los Angeles (UCLA) and specializes in trading the biotechnology sector.
Kyle has extensive experience in researching, writing, and editing articles that have been published in scientific journals. He uses these experiences to write and comment about the potential of various biotechnology companies. Kyle specializes in evaluating trial success, drug potential, and market valuations.
As an investor/trader, Kyle likes to focus on chart analysis and investor/trader sentiment to identify good entry and exit points.
Kyle can also be followed at www.twitter.com/kylewdennis @kylewdennis
Michael Kovar; writer, editor, investor, trader and team member of stockmatusow.com
Michael has spent over ten years in financial roles with companies large and small. Recently, he spent time in a consulting role with Thomson Reuters legal headquarters in Eagan, MN. He currently works in an analyst position with a healthcare organization. Since 2011, Michael has worked with Scott Matusow to help research and edit articles for Stockmatusow.com.
Michael can be followed at www.twitter.com/MMK_3399 @MMK_3399
Gravity Research is an organization composed of financial analysts with experience working at top investment banks and buyside firms as well as industry veterans who are experts in their fields. We engage in careful research on publicly traded companies that we believe offer compelling long or short investment opportunities, and present our best ideas to the public.
I currently work in the health care field. I am a long-term investor who conducts extensive research as part of my due diligence when considering a stock. My articles hope to provide unbiased background information to help others make an educated decision.
Although I recommend a diversified portfolio, I have a special interest in biomedical firms. Since biomedical investing is often very risky, I believe that research is especially important when investing in this industry. I find biomedical investing rewarding because these investments may not only yield high returns but also help save lives.
Over seven years of experience making contrarian bets based on my macro view and stock-specific turnaround stories to garner outsized returns with a favorable risk/reward profile. If you want me to cover a specific stock or have a question for an article, just let me know!
Bookmark QTR's new blog, where exclusive (and always FREE) content will be available: http://www.quoththeravenresearch.com
Visit QTR and check out trading ideas, commentary, and me arguing with idiots on Twitter: http://www.twitter.com/quoththeravensa
QTR's ARTICLES ARE BOUND BY SA'S CONTRIBUTOR POLICY IN ADDITION TO THIS ENTIRE LENGTHY, YET EXTREMELY PERTINENT ADD ON DISCLOSURE, WHICH SERVES AS BOTH A STANDALONE DISCLOSURE AND AN AMENDMENT TO ANY AND ALL DISCLOSURES ALREADY PRESIDING OVER SEEKING ALPHA:
Quoth the Raven's ("QTR") articles are the sole product of QTR and his personal, individual opinions. These articles are not associated with, in any way, the opinions, strategies, or works of QTR's employer, associates, or entities in any way otherwise related to QTR.
(i.e. This are solely my personal thoughts and opinions)
You agree that by reading Quoth the Raven's articles, you are acting at your OWN RISK. In NO EVENT should QTR be liable for any direct or indirect trading losses caused by any information contained in QTR's articles, StockTalks, or other internet-based dissemination methods. Information in QTR's articles are not an offer to sell or a solicitation of an offer to buy any security, nor shall any security be offered or sold to any person, in any jurisdiction in which such offer would be unlawful under the securities laws of such jurisdiction. QTR is not suggesting the transacting of any financial instruments and QTR suggests consulting your personal financial adviser with regards to any such transactions.
QTR makes no representations, and specifically disclaims all warranties, express, implied, or statutory, regarding the accuracy, timeliness, or completeness of any material contained in this site. Again, you should seek the advice of your personal financial adviser or a security professional regarding your stock transactions.
QTR does not, in any way, guarantee that he is providing all of the information that may be available on any topic written. QTR recommends, again, that you do your own due diligence and consult a registered financial adviser before buying or selling any security.
QTR most always holds a position in any of the securities profiled in his pieces and he constructs his SA disclosures in accordance with SA's Contributor Policy, to the best of his knowledge in order to maintain transparency and also to uphold and respect pertinent securities laws. QTR may or may not report when a position is initiated or covered. Each investor must make that decision based on his/her judgment of the market.
I am not a stockbroker or financial adviser. I am a casual investor making casual observations for the purpose of discussion and open communication and analysis of companies and stocks. All articles are my opinion only and are not suggestions to buy or sell any equity, bond, option or other financial instrument. QTR may have long or short positions in any tickers mentioned at any time and reserves the right to open, close, or modify positions at all time without notice. My conclusions are the result of my personal due diligence and have been wrong in the past. There are tons of unqualified people out there offering up financial advice and its your responsibility to sort through the BS. You don't hit the button to fill my orders and I don't hit yours, so no whining or praising over stocks covered by me.
Follow QTR on Twitter: https://twitter.com/QuoththeRavenSA
View QTR's Stock Picking Performance for every article at TipRanks:
Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event driven, value-oriented investment opportunities. Rangeley Capital and his value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for its investors and then Mr. DeMuth writes about them on StW.